Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 78 citing articles:

Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Yen‐Ju Lin, Martina Anzaghe, Stefan Schülke
Cells (2020) Vol. 9, Iss. 4, pp. 880-880
Open Access | Times Cited: 689
GM-CSF in inflammation
John A. Hamilton
The Journal of Experimental Medicine (2019) Vol. 217, Iss. 1
Open Access | Times Cited: 230
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches
Frederick Lang, Ming-Chin Lee, John R. Teijaro, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 8, pp. 507-514
Open Access | Times Cited: 216
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Mohamed A. Alfaleh, Hashem O. Alsaab, Ahmad Bakur Mahmoud, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 216
Novel insights into macrophage diversity in rheumatoid arthritis synovium
Marie‐Astrid Boutet, Gabriel Courties, Alessandra Nerviani, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 3, pp. 102758-102758
Closed Access | Times Cited: 125
Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
Jianan Zhao, Shicheng Guo, Steven J. Schrodi, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 106
The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages
Eri Matsubara, Hiromu Yano, Cheng Pan, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2250-2250
Open Access | Times Cited: 64
The role of inflammation in autoimmune disease: a therapeutic target
Yu Xiang, Mingxue Zhang, D.Y. Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 53
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets
Ming Li, Mengjie Wang, Yuanjia Wen, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 47
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Fan Guan, Ruixuan Wang, Zhenjie Yi, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
Aldo Bonaventura, Alessandra Vecchié, Tisha S. Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 131
<p>GM-CSF: A Promising Target in Inflammation and Autoimmunity</p>
Ming-Chin Lee, Adrian Achuthan, John A. Hamilton
ImmunoTargets and Therapy (2020) Vol. Volume 9, pp. 225-240
Open Access | Times Cited: 94
The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review
Ali Ataya, Vijaya Knight, Brenna Carey, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 48
The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma
Yusuke Shinchi, Shiho Ishizuka, Yoshihiro Komohara, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 11, pp. 2645-2661
Open Access | Times Cited: 36
Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches
Ogugua Ndili, Lesley Ann Saketkoo, Anne‐Marie Russell, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 32
Roles of trained immunity in the pathogenesis of periodontitis
Yingyi Li, Yue Chen, Guanhui Cai, et al.
Journal of Periodontal Research (2023) Vol. 58, Iss. 5, pp. 864-873
Closed Access | Times Cited: 21
Updates on ankylosing spondylitis: pathogenesis and therapeutic agents
Se Hee Kim, Sang‐Hoon Lee
Journal of Rheumatic Diseases (2023) Vol. 30, Iss. 4, pp. 220-233
Open Access | Times Cited: 18
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects
Chiara Crotti, Elena Agape, Andrea Becciolini, et al.
Drugs (2019) Vol. 79, Iss. 16, pp. 1741-1755
Closed Access | Times Cited: 45
Targeting GM-CSF in inflammatory and autoimmune disorders
Adrian Achuthan, Ming-Chin Lee, John A. Hamilton
Seminars in Immunology (2021) Vol. 54, pp. 101523-101523
Closed Access | Times Cited: 39
GM-CSF: Master regulator of the T cell-phagocyte interface during inflammation
Florian Ingelfinger, Donatella De Feo, Burkhard Becher
Seminars in Immunology (2021) Vol. 54, pp. 101518-101518
Open Access | Times Cited: 38
GM-CSF Expression and Macrophage Polarization in Joints of Undifferentiated Arthritis Patients Evolving to Rheumatoid Arthritis or Psoriatic Arthritis
Sara Fuentelsaz-Romero, Andrea Cuervo, Lizbeth Estrada‐Capetillo, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 35
Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives
Jacek Plichta, Piotr Kuna, Michał Panek
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
Roy Fleischmann, Désirée van der Heijde, Vibeke Strand, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 12, pp. 1516-1526
Open Access | Times Cited: 15
Targeting cytokine networks in neuroinflammatory diseases
Burkhard Becher, Tobias Derfuß, Roland Liblau
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 11, pp. 862-879
Closed Access | Times Cited: 5
Repurposed Drugs, Molecular Vaccines, Immune‐Modulators, and Nanotherapeutics to Treat and Prevent COVID‐19 Associated with SARS‐CoV‐2, a Deadly Nanovector
Taru Dube, Amrito Ghosh, Jibanananda Mishra, et al.
Advanced Therapeutics (2020) Vol. 4, Iss. 2
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top